Antidiabetic, antioxidant and antihyperlipidemic status of Heliotropium zeylanicum extract on streptozotocin-induced diabetes in rats
| Autor: | Veerendra C. Yeligar, Deepak Kumar Dash, Pinaki Sengupta, Tapan Kumar Maity, K. Murugesh, Bhim Chandra Maiti |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Blood Glucose
Male Antioxidant Thiobarbituric acid medicine.medical_treatment Tolbutamide Hypercholesterolemia Drinking Pharmaceutical Science Administration Oral Heliotropium Pharmacology Thiobarbituric Acid Reactive Substances Antioxidants Streptozocin Diabetes Mellitus Experimental Superoxide dismutase Phytomedicine chemistry.chemical_compound Eating Oral administration Diabetes mellitus medicine Animals Hypoglycemic Agents Rats Wistar Hypolipidemic Agents Hypertriglyceridemia biology Plant Extracts Superoxide Dismutase Body Weight General Medicine Streptozotocin medicine.disease Catalase Glutathione Rats chemistry Liver biology.protein medicine.drug Phytotherapy |
| Zdroj: | Biologicalpharmaceutical bulletin. 29(11) |
| ISSN: | 0918-6158 |
| Popis: | The potential role of the methanolic extract of Heliotropium zeylanicum (BURM.F) LAMK (MEHZ) in the treatment of diabetes along with its antioxidant and antihyperlipidemic effects was studied in streptozotocin-induced diabetic rats. Oral administration of (MEHZ) 150 and 300 mg/kg/d for 14 d significantly decreased the blood glucose level and considerably increased the body weight, food intake, and liquid intake of diabetic-induced rats. MEHZ significantly decreased thiobarbituric acid reactive substances and significantly increased reduced glutathione, superoxide dismutase and catalase in streptozotocin-induced diabetic rats at the end of 14 d of treatment. The study also investigated the antihyperlipidemic potential of MEHZ. The results show that the active fraction of MEHZ is promising for development of a standardized phytomedicine for the treatment of diabetes mellitus. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|